Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 29 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 29 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 05 Sep 2017 Results published in the Blood